Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ampsource Biopharma
Shanghai, Shanghai, Chinaampsourcebio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The lead asset, a recombinant FGF21-Fc fusion protein targeting the fibroblast growth factor receptor pathway, has reached phase II clinical trials for non-alcoholic steatohepatitis. Other pipeline programs are in phase I or preclinical stages targeting hemophilia A, type II diabetes mellitus, oncology/neoplasms, autoimmune disease, and other metabolic disorders. The company emphasizes best-in-class potential and differentiated long‑acting biologics that aim to be affordable to patients.
- Therapeutic areas
- HematologyGastroenterologyEndocrinologyOncologyImmunology
- Modalities
- Fusion proteinMonoclonal antibodyRecombinant protein
- Industry
- Biotech
Beyond the preview
Go deeper on Ampsource Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ampsource Biopharma.